A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

NCT05899816 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis

Interventions

DRUG: Rocatinlimab
DRUG: Placebo

Sponsor

Amgen